SMFM's 41st Annual Pregnancy Meeting

Working together for the global advancement of safe and healthy pregnancies

January 25 - 30, 2021

Industry-Sponsored Learning Session - Momenta Presents: Nipocalimab: A Novel FcRn-Antibody Under Investigation for Hemolytic Disease of the Fetus and Newborn

Jan. 27, 2021 3 - 4pm

The symposium will provide information on nipocalimab, a novel anti-FcRn therapy, currently being investigated in a phase 2 trial for treatment of hemolytic diseases of the fetus and newborn (HDFN). The objectives of the presentation are to review HDFN, the proposed mechanism of action of nipocalimab, the design of the phase 2 trial, and future possibilities of nipocalimab in the Maternal-Fetal Medicine space.

Eleonor Tiblad, MD - Karolinksa Institute, Stockholm, Sweden
Kara Markham, MD - 
University of Cincinnati Health, Cincinnati, OH

Price: $0.00